BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$24.88 USD
+0.55 (2.26%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $24.91 +0.03 (0.12%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for BridgeBio Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 452 | 510 | 837 | 607 | 546 |
Receivables | 2 | 17 | 20 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 24 | 22 | 32 | 36 | 23 |
Total Current Assets | 478 | 549 | 889 | 643 | 569 |
Net Property & Equipment | 12 | 15 | 30 | 20 | 6 |
Investments & Advances | 0 | 0 | 0 | 0 | 31 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 26 | 29 | 45 | 0 | 0 |
Deposits & Other Assets | 23 | 20 | 33 | 24 | 26 |
Total Assets | 546 | 623 | 1,013 | 704 | 632 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 12 | 12 | 9 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 123 | 98 | 118 | 76 | 39 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 8 | 0 | 6 | 4 |
Total Current Liabilities | 144 | 121 | 135 | 96 | 60 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,727 | 1,708 | 1,704 | 476 | 92 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 27 | 22 | 10 | 4 |
Minority Interest (Liabilities) | 0 | -2 | 1 | 2 | 2 |
Total Liabilities | 1,889 | 1,866 | 1,880 | 597 | 158 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,481 | 939 | 842 | 1,021 | 848 |
Retained Earnings | -2,561 | -1,918 | -1,437 | -889 | -440 |
Other Equity | 11 | 11 | 3 | 49 | 66 |
Treasury Stock | 275 | 275 | 275 | 75 | 0 |
Total Shareholder's Equity | -1,343 | -1,243 | -867 | 106 | 474 |
Total Liabilities & Shareholder's Equity | 546 | 623 | 1,013 | 704 | 632 |
Total Common Equity | -1,343 | -1,243 | -867 | 106 | 474 |
Shares Outstanding | 173.90 | 149.40 | 147.10 | 122.70 | 123.50 |
Book Value Per Share | -7.72 | -8.32 | -5.89 | 0.87 | 3.84 |
Fiscal Year End for BridgeBio Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 452 | 560 | 404 | 517 |
Receivables | NA | 2 | 5 | 9 | 11 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 24 | 23 | 21 | 25 |
Total Current Assets | NA | 478 | 588 | 433 | 553 |
Net Property & Equipment | NA | 12 | 12 | 13 | 14 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 26 | 27 | 28 | 28 |
Deposits & Other Assets | NA | 23 | 19 | 20 | 21 |
Total Assets | NA | 546 | 655 | 504 | 626 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 11 | 4 | 4 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 123 | 91 | 96 | 82 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 6 | 7 | 6 | 7 |
Total Current Liabilities | NA | 144 | 106 | 110 | 97 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 1,727 | 1,721 | 1,719 | 1,713 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 12 | 13 | 18 | |
Minority Interest (Liabilities) | NA | 0 | 1 | 0 | 0 |
Total Liabilities | NA | 1,889 | 1,850 | 1,854 | 1,839 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,481 | 1,460 | 1,128 | 1,107 |
Retained Earnings | NA | -2,561 | -2,392 | -2,215 | -2,057 |
Other Equity | NA | 11 | 12 | 12 | 12 |
Treasury Stock | NA | 275 | 275 | 275 | 275 |
Total Shareholder's Equity | NA | -1,343 | -1,195 | -1,350 | -1,213 |
Total Liabilities & Shareholder's Equity | NA | 546 | 655 | 504 | 626 |
Total Common Equity | 0 | -1,343 | -1,195 | -1,350 | -1,213 |
Shares Outstanding | 175.80 | 173.90 | 173.90 | 161.40 | 160.50 |
Book Value Per Share | 0.00 | -7.72 | -6.87 | -8.36 | -7.56 |